Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467676 | 0.97 | GRIN2D (0.47) | DPP4AKR1C1GRIN2DGRIN3BCYP2B6 | |
| SCHEMBL5925064 | 0.95 | DPP4 (0.41) | DPP4AKR1C1GRIN2DGRIN3BCYP2B6 | |
| SCHEMBL498013 | 0.89 | OPRM1 (0.44) | DPP4AKR1C1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16878896 | 0.78 | OPRM1 (0.61) | OPRM1 | |
| SCHEMBL8116292 | 0.75 | SLC6A3 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| Ammonia Solution, Strong SCHEMBL27575342 | 0.75 | SLC6A3 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9037762 | 0.75 | SLC6A3 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5259881 | 0.75 | OPRM1 (0.55) | GRIN2DGRIN3BSLC6A4GRIN1KCNH2 | |
| SCHEMBL23628451 | 0.74 | DPP4 (0.46) | DPP4AKR1C1GRIN2DGRIN3BCYP2B6 | |
| Ammonia Solution, Strong SCHEMBL8967959 | 0.74 | ESR1 (0.56) | GRIN2DGRIN3BCYP2B6SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | V-BAC HOLDING CORP. (CA) | 2015-09-24 | — | — | US | claimed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | claimed |
| EP-1663962-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORP (US) | 2007-08-22 | — | — | EP | claimed |
| JP-2007503392-A | — | — | 2007-02-22 | — | — | JP | claimed |
| EP-1663962-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | DENDREON CORPORATION (US) | 2005-03-10 | — | — | US | claimed |
| WO-2005020897-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2005-03-10 | — | — | WO | claimed |
| EP-1053224-B1 | BIPHENYLSULFONYL CYANAMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS A MEDICAMENT | AVENTIS PHARMA GMBH (DE) | 2002-08-21 | — | — | EP | claimed |
| US-6369069-B1 | CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | claimed |
| CN-103772239-B | amide and amidine derivatives and uses thereof | ABBVIE 公司 | 2017-04-12 | — | — | CN | disclosed |
| CN-103848806-B | Glucopyranosyl derivatives, its preparation method and in application pharmaceutically | SUNSHINE LAKE PHARMA CO.,LTD. (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-103319445-B | Crystalline structure of SGLT2 inhibitor and preparation method thereof | ASTRAZENECA AB (SE) | 2016-01-20 | — | — | CN | disclosed |
| CN-105193761-A | BILAYER TABLET FORMULATIONS | ASTRAZENECA AB | 2015-12-30 | — | — | CN | disclosed |
| CN-102711739-B | Bilayer tablet | ASTRAZENECA AB (SE) | 2015-12-16 | — | — | CN | disclosed |
| EP-0623608-A1 | BENZOPYRAN DERIVATIVE, PRODUCTION THEREOF, AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1994-11-09 | — | — | EP | disclosed |
| EP-0547178-A4 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER LAMBERT CO (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0547178-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0546177-A1 | BENZOPYRAN DERIVATIVE, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1993-06-16 | — | — | EP | disclosed |
| EP-0495982-A1 | BICYCLIC PYRIMIDINE DERIVATIVE, METHOD OF PRODUCING THE SAME, AND PHARMACEUTICAL PREPARATION CONTAINING THE SAME AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 1992-07-29 | — | — | EP | disclosed |
| WO-1992004045-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | DPP4 2440/4885AKR1C1 3419/4885GRIN2D 3960/4885 |
| US-20150266810-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | DPP4 2609/4885AKR1C1 3607/4885GRIN2D 3932/4885 |
| US-20050054651-A1 | Compositions and methods for the treatment of disease associated with Trp-p8 expression | TRPC4, TRPC3, TRPC1 | DPP4 2440/4885AKR1C1 3419/4885GRIN2D 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.